Virtual and Decentralized Clinical Trials (VCT) Market Size, Share, Trends, and Forecast, 2026-2036 | AI, Wearables, and Hybrid Models Propel Market to USD 26.8 Billion at 11% CAGR

Virtual and Decentralized Clinical Trials (VCT) Market Size, Share, Trends, and Forecast, 2026-2036 | AI, Wearables, and Hybrid Models Propel Market to USD 26.8 Billion at 11% CAGR Dublin, Oct. 05, 2026 (GLOBE NEWSWIRE) -- "Virtual Clinical Trials (VCT) Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.

The global Virtual Clinical Trials market is estimated at USD 9.4 billion in 2026 and is projected to reach USD 26.8 billion by 2036, expanding at a CAGR of 11.0% during the forecast period. Market growth is being supported by the widespread adoption of decentralized clinical trials across pharmaceutical and biotechnology research programs, as well as continued investment in digital health platforms, remote patient monitoring, and technology-enabled clinical operations.

Telemedicine, eConsent, eCOA and ePRO applications, wearable sensors, direct-to-patient drug delivery, and remote monitoring platforms are increasingly integrated into clinical trial protocols. These capabilities allow sponsors to improve patient access, streamline data collection, reduce operational costs, and minimize dependence on repeated visits to designated research sites. Virtual trial models have moved beyond pandemic-era adoption and now represent an established component of pharmaceutical R&D strategies.

Virtual Clinical Trials Market Dynamics

Patient recruitment and retention remain major growth drivers. Conventional site-based trials can exclude eligible participants because of travel requirements, time commitments, mobility limitations, and geographic distance. Decentralized approaches can broaden access to clinical research and improve enrollment among patient populations that may otherwise be difficult to reach.

Rising clinical trial costs are also accelerating adoption. Site management, patient travel reimbursement, clinical monitoring, and administrative coordination account for a significant portion of Phase II and Phase III expenses. Virtual clinical trial platforms can reduce these costs by supporting remote participation, centralized data collection, and risk-based monitoring.

Regulatory clarity has improved through updated guidance for decentralized trial design and execution. However, sponsors and technology providers must continue to address data security, platform interoperability, direct-to-patient drug delivery logistics, protocol compliance, and the integration of remote data streams into unified clinical databases.

Artificial intelligence, real-world evidence, and clinical-grade wearable technologies are creating additional market opportunities. AI-powered tools can support patient identification through electronic health record analysis, while validated wearable endpoints can expand the range of conditions assessed through remote participation. These developments are expected to improve trial scalability, patient engagement, and endpoint evaluation.

Market Segment Analysis

The report evaluates the Virtual Clinical Trials market by trial model, component, phase, therapeutic area, indication type, end user, and geography. Hybrid trials currently hold the largest market share because they combine selected site visits with remote participation. This model enables sponsors to retain established clinical infrastructure while improving patient convenience and access.

Fully virtual trials are expected to record the highest growth rate as regulatory frameworks, validated digital endpoints, and end-to-end technology platforms continue to mature. Software and platforms account for the largest component share because they support patient engagement, electronic consent, data capture, monitoring, analytics, and trial management. Devices and infrastructure, particularly wearable technologies, are projected to experience rapid growth as remotely collected clinical endpoints gain wider acceptance.

Oncology represents the largest therapeutic area within the market. Rare diseases are expected to deliver strong growth because decentralized models can connect geographically dispersed patients with specialized research programs while reducing the burden of frequent travel.

Regional Market Outlook

North America leads the global Virtual Clinical Trials market, supported by advanced clinical research infrastructure, substantial sponsor investment, an established network of contract research organizations and technology providers, and FDA guidance on decentralized clinical trials.

Europe continues to expand as the European Medicines Agency and updated Good Clinical Practice guidelines provide greater regulatory direction. Asia-Pacific is projected to register the fastest growth through 2036, supported by large patient populations, skilled clinical investigators, expanding digital health adoption, and regulatory alignment across Japan, South Korea, China, and Singapore. Latin America and the Middle East & Africa also present emerging opportunities as clinical research capabilities and digital infrastructure improve.

Competitive Landscape

Competition is shaped by platform integration, regulatory expertise, patient engagement capabilities, clinical trial experience, geographic reach, and partnership strategies. Market participants are strengthening their positions through acquisitions, technology development, geographic expansion, and broader end-to-end decentralized trial offerings.

Companies profiled include Medable Inc., Science 37 Holdings Inc., Parexel International Corporation, IQVIA Inc., ICON plc, Labcorp Drug Development, Oracle Corporation Clinical Platforms, Veeva Systems Inc., Medidata Solutions (Dassault Systemes), Signant Health, Clario, Castor EDC, ObvioHealth, Thread Research, and Curebase, among others.

Report Benefits

The report delivers actionable market intelligence for contract research organizations, pharmaceutical and biotechnology companies, digital platform providers, medical device companies, investors, and consultants seeking to evaluate growth opportunities within the global Virtual Clinical Trials market.

Key Topics Covered

1. Introduction

1.1. Market Definition

1.2. Scope

1.3. Market Ecosystem

1.4. Currency and Limitations

1.4.1. Currency

1.4.2. Limitations

1.5. Key Stakeholders

2. Research Methodology

2.1. Research Approach

2.2. Data Collection & Validation

2.2.1. Secondary Research

2.2.2. Primary Research (Pharma, CROs, Tech Providers, Regulators)

2.3. Market Estimation

2.3.1. Bottom-Up Approach

2.3.2. Top-Down Approach

2.3.3. Forecast Modeling

2.4. Data Triangulation

2.5. Assumptions

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Market Dynamics

4.2.1. Drivers

4.2.1.1. Need to Improve Patient Recruitment & Retention

4.2.1.2. Rising Adoption of Digital Health Technologies

4.2.1.3. Increasing Cost & Complexity of Traditional Trials

4.2.1.4. Demand for Patient-Centric Trial Models

4.2.2. Restraints

4.2.2.1. Regulatory Uncertainty Across Regions

4.2.2.2. Data Privacy & Security Concerns

4.2.2.3. Limited Digital Literacy Among Patients

4.2.3. Opportunities

4.2.3.1. Integration with AI & Real-World Evidence (RWE)

4.2.3.2. Expansion in Emerging Markets

4.2.3.3. Growth in Remote Monitoring & Wearables

4.2.3.4. Hybrid Trial Models Adoption

4.2.4. Challenges

4.2.4.1. Standardization of Digital Protocols

4.2.4.2. Interoperability of Platforms

4.3. Technology Landscape

4.3.1. Telemedicine & Virtual Patient Visits

4.3.2. Wearable Devices & Remote Monitoring Sensors

4.3.3. Electronic Clinical Outcome Assessments (eCOA)

4.3.4. eConsent Platforms

4.3.5. Cloud-Based Clinical Trial Platforms

4.3.6. AI & Data Analytics in Clinical Trials

4.4. Virtual Clinical Trials Ecosystem

4.4.1. Pharmaceutical & Biotechnology Companies

4.4.2. Contract Research Organizations (CROs)

4.4.3. Technology & Platform Providers

4.4.4. Healthcare Providers & Investigators

4.4.5. Patients & Participants

4.5. Value Chain Analysis

4.5.1. Trial Design & Protocol Development

4.5.2. Patient Recruitment & Enrolment

4.5.3. Data Collection & Monitoring

4.5.4. Data Analysis & Reporting

4.5.5. Regulatory Submission

4.6. Regulatory Landscape

4.6.1. FDA Guidelines for Decentralized Trials

4.6.2. EMA & Global Regulatory Frameworks

4.6.3. Data Privacy Regulations (HIPAA, GDPR)

4.7. Industry Trends

4.7.1. Rise of Hybrid Clinical Trials

4.7.2. Patient-Centric Trial Design

4.7.3. Digital Transformation in Clinical Research

4.7.4. Increasing Use of Real-World Data

4.8. Cost and Pricing Analysis

4.8.1. Cost Comparison: Traditional vs Virtual Trials

4.8.2. Cost Drivers by Trial Phase

4.8.3. ROI and Efficiency Gains

5. Virtual Clinical Trials Market, by Trial Model

5.1. Introduction

5.2. Fully Virtual Trials

5.3. Hybrid Trials (On-site + Remote)

5.4. Site-Based Digital Trials

6. Virtual Clinical Trials Market, by Component

6.1. Introduction

6.2. Software & Platforms

6.2.1. Clinical Trial Management Systems (CTMS)

6.2.2. eConsent Solutions

6.2.3. eCOA & ePRO Platforms

6.2.4. Telemedicine Platforms

6.2.5. Data Analytics & AI Platforms

6.3. Services

6.3.1. CRO Services

6.3.2. Patient Recruitment Services

6.3.3. Remote Monitoring Services

6.4. Devices & Infrastructure

6.4.1. Wearables

6.4.2. Remote Monitoring Devices

6.4.3. Mobile Devices

7. Virtual Clinical Trials Market, by Phase

7.1. Phase I

7.2. Phase II

7.3. Phase III (Largest Segment)

7.4. Phase IV

8. Virtual Clinical Trials Market, by Therapeutic Area

8.1. Oncology (Largest Segment)

8.2. Cardiovascular Diseases

8.3. Neurology

8.4. Infectious Diseases

8.5. Metabolic Disorders

8.6. Rare Diseases

8.7. Other Therapeutic Areas

9. Virtual Clinical Trials Market, by Indication Type

9.1. Chronic Diseases

9.2. Acute Diseases

9.3. Rare Diseases

10. Virtual Clinical Trials Market, by End User

10.1. Pharmaceutical Companies

10.2. Biotechnology Companies

10.3. CROs

10.4. Academic & Research Institutes

11. Virtual Clinical Trials Market, by Geography

11.1. Introduction

11.2. North America

11.2.1. U.S.

11.2.2. Canada

11.3. Europe

11.3.1. Germany

11.3.2. U.K.

11.3.3. France

11.3.4. Italy

11.3.5. Spain

11.3.6. Netherlands

11.3.7. Sweden

11.3.8. Switzerland

11.3.9. Rest of Europe

11.4. Asia-Pacific

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. South Korea

11.4.5. Australia

11.4.6. Singapore

11.4.7. Rest of Asia-Pacific

11.5. Latin America

11.5.1. Brazil

11.5.2. Mexico

11.5.3. Rest of Latin America

11.6. Middle East & Africa

11.6.1. UAE

11.6.2. Saudi Arabia

11.6.3. South Africa

11.6.4. Rest of MEA

12. Competitive Landscape

12.1. Overview

12.2. Key Growth Strategies

12.3. Competitive Benchmarking

12.4. Competitive Dashboard

12.4.1. Industry Leaders

12.4.2. Market Differentiators

12.4.3. Emerging Players

12.5. Market Ranking/Positioning Analysis

13. Company Profiles

Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis

13.1. Medable, Inc.

13.2. Science 37 Holdings, Inc.

13.3. Parexel International Corporation

13.4. IQVIA Inc.

13.5. ICON plc

13.6. Labcorp Drug Development

13.7. Oracle Corporation (Clinical Platforms)

13.8. Veeva Systems Inc.

13.9. Medidata Solutions (Dassault Systemes)

13.10. Signant Health

13.11. Clario

13.12. Castor EDC

13.13. ObvioHealth

13.14. Thread Research

13.15. Curebase

14. Appendix

14.1. Customization Options

14.2. Related Reports

For more information about this report visit https://www.researchandmarkets.com/r/sw5rnt

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.